ENCePP checklist.

Study title:
Dynamics of prescription drug use, diagnoses and healthcare utilization after community managed SARS-CoV-2 infection

EU PAS Register® number:
Study reference number (if applicable):

Section 1: Milestones	**Yes**	**No**	**N/A**	**Section Number**
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection[1]	X	☐	☐	5
1.1.2 End of data collection[2]	X	☐	☐	5
1.1.3 Progress report(s)	☐	☐	X	-
1.1.4 Interim report(s)	☐	☐	X	-
1.1.5 Registration in the EU PAS Register®	X	☐	☐	5
1.1.6 Final report of study results.	X	☐	☐	5

Comments:

Section 2: Research question	**Yes**	**No**	**N/A**	**Section Number**
2.1 Does the formulation of the research question and objectives clearly explain:	☐	☐	☐	
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	X	☐	☐	1
2.1.2 The objective(s) of the study?	X	☐	☐	1
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	X	☐	☐	2
2.1.4 Which hypothesis(-es) is (are) to be tested?	X	☐	☐	1, 2.5
2.1.5 If applicable, that there is no *a priori* hypothesis?	☐	☐	X	-

Comments:

Section 3: Study design	**Yes**	**No**	**N/A**	**Section Number**
3.1 Is the study design described? (e.g. cohort, case-control, cross-sectional, other design)	X	☐	☐	2, 2.3, 2.4, Fig. S1

[1] Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.
[2] Date from which the analytical dataset is completely available.

Section 3: Study design		**Yes**	**No**	**N/A**	**Section Number**
3.2	Does the protocol specify whether the study is based on primary, secondary or combined data collection?	X	☐	☐	2.2
3.3	Does the protocol specify measures of occurrence? (e.g., rate, risk, prevalence)	X	☐	☐	2.6
3.4	Does the protocol specify measure(s) of association? (e.g. risk, odds ratio, excess risk, rate ratio, hazard ratio, risk/rate difference, number needed to harm (NNH))	X	☐	☐	2.6
3.5	Does the protocol describe the approach for the collection and reporting of adverse events/adverse reactions? (e.g. adverse events that will not be collected in case of primary data collection)	☐	☐	X	-

Comments:

Adverse event reporting does not apply due to the study being based on secondary data

Section 4: Source and study populations		**Yes**	**No**	**N/A**	**Section Number**
4.1	Is the source population described?	X	☐	☐	2.1
4.2	Is the planned study population defined in terms of:				
	4.2.1 Study time period	X	☐	☐	2.1
	4.2.2 Age and sex	☐	☐	X	-
	4.2.3 Country of origin	X	☐	☐	2.1
	4.2.4 Disease/indication	X	☐	☐	2.1
	4.2.5 Duration of follow-up	X	☐	☐	2.4
4.3	Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	X	☐	☐	2.1, 2.3

Comments:

Definition of the study population in terms of age and sex is not applicable, due to any individual (adults, children, males, females) who was tested for SARS-CoV-2 being eligible for inclusion in the study.

Section 5: Exposure definition and measurement		**Yes**	**No**	**N/A**	**Section Number**
5.1	Does the protocol describe how the study exposure is defined and measured? (e.g. operational details for defining and categorising exposure, measurement of dose and duration of drug exposure)	X	☐	☐	2.3
5.2	Does the protocol address the validity of the exposure measurement? (e.g. precision, accuracy, use of validation sub-study)	X	☐	☐	3.2
5.3	Is exposure categorised according to time windows?	☐	X	☐	-

Section 5: Exposure definition and measurement	**Yes**	**No**	**N/A**	**Section Number**
5.4 Is intensity of exposure addressed? (e.g. dose, duration)	X	☐	☐	2.3
5.5 Is exposure categorised based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	☐	☐	X	
5.6 Is (are) (an) appropriate comparator(s) identified?	X	☐	☐	2.3

Comments:

5.4: Separate cohorts for community managed and hospitalized SARS-CoV-2 infection

Section 6: Outcome definition and measurement	**Yes**	**No**	**N/A**	**Section Number**
6.1 Does the protocol specify the primary and secondary (if applicable) outcome(s) to be investigated?	X	☐	☐	2.5
6.2 Does the protocol describe how the outcomes are defined and measured?	X	☐	☐	2.5, Appendix A + B
6.3 Does the protocol address the validity of outcome measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, use of validation sub-study)	☐	X	☐	-
6.4 Does the protocol describe specific outcomes relevant for Health Technology Assessment? (e.g. HRQoL, QALYs, DALYS, health care services utilisation, burden of disease or treatment, compliance, disease management)	☐	X	☐	-

Comments:

6.3: Not practical due to the large amount of possible outcomes.

Section 7: Bias	**Yes**	**No**	**N/A**	**Section Number**
7.1 Does the protocol address ways to measure confounding? (e.g. confounding by indication)	X	☐	☐	2.5, 2.6
7.2 Does the protocol address selection bias? (e.g. healthy user/adherer bias)	X	☐	☐	3.1
7.3 Does the protocol address information bias? (e.g. misclassification of exposure and outcomes, time-related bias)	X	☐	☐	3.1

Comments:

Section 8: Effect measure modification	**Yes**	**No**	**N/A**	**Section Number**
8.1 Does the protocol address effect modifiers? (e.g. collection of data on known effect modifiers, sub-group analyses, anticipated direction of effect)	X	☐	☐	2.6, Figure 1

Comments:

8.1: Select analyses will be repeated among different age groups, due to age being a potential effect modifier

Section 9: Data sources	**Yes**	**No**	**N/A**	**Section Number**
9.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
9.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview)	X	☐	☐	2.2
9.1.2 Outcomes? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics)	X	☐	☐	2.2, 2.5, appendix A, B
9.1.3 Covariates and other characteristics?	X	☐	☐	2.2
9.2 Does the protocol describe the information available from the data source(s) on:				
9.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	X	☐	☐	2.2
9.2.2 Outcomes? (e.g. date of occurrence, multiple event, severity measures related to event)	X	☐	☐	2.2,2.5,2.6
9.2.3 Covariates and other characteristics? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, lifestyle)	X	☐	☐	2.2
9.3 Is a coding system described for:				
9.3.1 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	X	☐	☐	2.5
9.3.2 Outcomes? (e.g. International Classification of Diseases (ICD), Medical Dictionary for Regulatory Activities (MedDRA))	X	☐	☐	2.5
9.3.3 Covariates and other characteristics?	X	☐	☐	2.2
9.4 Is a linkage method between data sources described? (e.g. based on a unique identifier or other)	X	☐	☐	2.2

Comments:

Section 10: Analysis plan	**Yes**	**No**	**N/A**	**Section Number**
10.1 Are the statistical methods and the reason for their choice described?	X	☐	☐	2.6
10.2 Is study size and/or statistical precision estimated?	X	☐	☐	2.3

Section 10: Analysis plan	**Yes**	**No**	**N/A**	**Section Number**
10.3 Are descriptive analyses included?	X	☐	☐	2.6
10.4 Are stratified analyses included?	X	☐	☐	2.6
10.5 Does the plan describe methods for analytic control of confounding?	X	☐	☐	2.6
10.6 Does the plan describe methods for analytic control of outcome misclassification?	☐	X	☐	-
10.7 Does the plan describe methods for handling missing data?	☐	☐	X	-
10.8 Are relevant sensitivity analyses described?	X	☐	☐	2.7

Comments:

10.7: Methods for handling of missing data were not described, as we do not expect any missing data.

Section 11: Data management and quality control	**Yes**	**No**	**N/A**	**Section Number**
11.1 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	X	☐	☐	6
11.2 Are methods of quality assurance described?	X	☐	☐	6
11.3 Is there a system in place for independent review of study results?	X	☐	☐	7

Comments:

Section 12: Limitations	**Yes**	**No**	**N/A**	**Section Number**
12.1 Does the protocol discuss the impact on the study results of:				
12.1.1 Selection bias?	X	☐	☐	3.1
12.1.2 Information bias?	X	☐	☐	3.1
12.1.3 Residual/unmeasured confounding? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods).	X	☐	☐	3.3
12.2 Does the protocol discuss study feasibility? (e.g. study size, anticipated exposure uptake, duration of follow-up in a cohort study, patient recruitment, precision of the estimates)	X	☐	☐	2.3

Comments:

Section 13: Ethical/data protection issues	**Yes**	**No**	**N/A**	**Section Number**
13.1 Have requirements of Ethics Committee/ Institutional Review Board been described?	X	☐	☐	4
13.2 Has any outcome of an ethical review procedure been addressed?	☐	☐	X	-
13.3 Have data protection requirements been described?	X	☐	☐	6

Comments:

Section 14: Amendments and deviations	**Yes**	**No**	**N/A**	**Section Number**
14.1 Does the protocol include a section to document amendments and deviations?	X	☐	☐	8

Comments:

Section 15: Plans for communication of study results	**Yes**	**No**	**N/A**	**Section Number**
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	X	☐	☐	7
15.2 Are plans described for disseminating study results externally, including publication?	X	☐	☐	7

Comments:

Name of the main author of the protocol: Lars Christian Lund

Date: 19/10/2020

Lars Christian Lund, Cand.Med.

Signature: _____